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Abstract
Background: A high prevalence of a variety of gastrointestinal (GI) symptoms is frequently reported in patients
with Autism Spectrum Disorders (ASD). The GI disturbances in ASD might be linked to gut dysbiosis representing
the observable phenotype of a “gut-brain axis” disruption. The exploitation of strategies which can restore normal
gut microbiota and reduce the gut production and absorption of toxins, such as probiotics addition/supplementation
in a diet, may represent a non-pharmacological option in the treatment of GI disturbances in ASD. The aim of this
randomized controlled trial is to determine the effects of supplementation with a probiotic mixture (Vivomixx®) in ASD
children not only on specific GI symptoms, but also on the core deficits of the disorder, on cognitive and language
development, and on brain function and connectivity. An ancillary aim is to evaluate possible effects of probiotic
supplementation on urinary concentrations of phthalates (chemical pollutants) which have been previously linked
to ASD.
Methods: A group of 100 preschoolers with ASD will be classified as belonging to a GI group or to a Non-GI (NGI)
group on the basis of a symptom severity index specific to GI disorders. In order to obtain four arms,
subjects belonging to the two groups (GI and NGI) will be blind randomized 1:1 to regular diet with
probiotics or with placebo for 6 months. All participants will be assessed at baseline, after three months
and after six months from baseline in order to evaluate the possible changes in: (1) GI symptoms; (2) autism symptoms
severity; (3) affective and behavioral comorbid symptoms; (4) plasmatic, urinary and fecal biomarkers related to
abnormal intestinal function; (5) neurophysiological patterns.
Discussion: The effects of treatments with probiotics on children with ASD need to be evaluated through rigorous
controlled trials. Examining the impact of probiotics not only on clinical but also on neurophysiological patterns, the
current trial sets out to provide new insights into the gut-brain connection in ASD patients. Moreover, results could
add information to the relationship between phthalates levels, clinical features and neurophysiological patterns in ASD.
Trial registration: ClinicalTrials.gov Identifier: NCT02708901. Retrospectively registered: March 4, 2016.
Keywords: Autism Spectrum Disorders (ASD), Gut-brain axis, Endophenotype, Probiotic Vivomixx®, Quantitative
electroencephalography (QEEG), Phtalates
* Correspondence: e.santocchi@fsm.unipi.it
1IRCCS Stella Maris Foundation, Viale del Tirreno 331, 56018 Calambrone,
Pisa, Italy
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Santocchi et al. BMC Psychiatry  (2016) 16:183 
DOI 10.1186/s12888-016-0887-5
Background
Autism Spectrum Disorders (ASD) comprise a com-
plex group of disorders of brain development charac-
terized by social and communication impairment
along with presence of repetitive and restrictive be-
haviors [1]. An elevated prevalence of gastrointestinal
(GI) dysfunction in individuals with ASD was first re-
ported by Goodwin and colleagues in 1971 [2], and
repeatedly confirmed in subsequent studies [3–9],
with prevalence rates ranging from 9 to 70 % [7, 10].
The most frequently reported GI symptoms were
alterations in bowel habits, chronic abdominal pain,
reflux and vomiting [8, 11–13]. It is notable that
untreated GI symptoms may increase behavioral prob-
lems in children with ASD [4, 14]. Several studies
reported also dysbiosis or various altered composition
of intestinal microbiota in ASD children [15–18]. In
particular, a greater representation of members of the
family of Clostridiales [16–18] and an increase of
Sutterella and Ruminococcus torques populations [19]
has been repeatedly revealed, the so called “gut-brain
axis” has been described as a physiological bidirec-
tional complex network of communication between
the brain and the gut [20–22] and it has been sug-
gested that this network is involved in neurodevelopment
[23–29] as well as in a variety of neuropsychiatric diseases
[30] including ASD [5, 22, 31, 32]. Therefore, the GI
disturbances in ASD might be linked to gut dysbiosis
representing the observable phenotype of a “gut-brain
axis” disruption [8, 15, 33, 34] characterized by intestinal
inflammation and alterations in intestinal function, often
described as a "leaky gut" [35].
Among the potential mechanisms by which gut micro-
biota can affect Central Nervous System (CNS) function,
there are the indirect effects on the innate immune sys-
tem through circulating levels of pro-inflammatory and
anti-inflammatory cytokines or through production of
metabolites (e.g. short chain fatty acids –SCFAs-) that
modulate the immune system and the sympathetic ner-
vous system [35]. In particular, changes in the gut micro-
biota are thought to be related to reduced integrity of
the intestinal barrier, leading to increased absorption of
toxins from the gut lumen and leakage of lipopolysac-
charides (LPS) and fatty acids. These molecules can act
upon Toll-like receptor 4 to activate systemic inflamma-
tion [36] which, in turn, affects critically also the CNS.
Growing evidence indicates that ASD pathogenesis may
involve brain inflammation associated with increased in-
flammatory biomarkers, such as Interleukin-6 (IL-6) and
Tumor Necrosis Factor-α (TNF-α) [36] and recent
studies have demonstrated that cytokines (in particular
adipokines) are the key molecules responsible for the im-
mune cell interaction. According to this view, Rodrigues
and colleagues [37] have found decreased levels of resistin
and increased levels of leptin in plasma of ASD subjects in
comparison with controls.
Another potential and noninvasive marker of intestinal
inflammation recently studied in ASD is calprotectin
[38], an abundant neutrophil protein found in the stool
that is markedly elevated in infectious and inflammatory
conditions, including Inflammatory Bowel Disease (IBD).
Other “gut-brain” interaction mechanisms are bidirec-
tional signalling via the vagal nerve, dysregulation of
metabolic pathways involved in production of neuro-
transmitters (such as serotonin and Gamma-Amino
Butyric Acid), and direct effects on the release of gut
peptides with modulatory functions from enteroendo-
crine cells [35].
All these mechanisms could interfere with brain devel-
opment and function, contributing to the pathogenesis
of ASD through modulation of brain neurotransmission
and connectivity, both at local and global level. In
particular, an alteration in brain connectivity is one of
the strongly supported neural underpinning of ASD
symptoms [39, 40]. Recently, Quantitative Electroen-
cephalography (QEEG), a non-invasive technique that
allows a highly precise measurement of brain function
and connectivity, has been applied to link neuro-
physiological patterns with ASD symptoms, in order
to characterize ASD subgroups and to evaluate the ef-
fect of treatment [41].
The research interest on GI problems in ASD is there-
fore based on its practical therapeutic importance as
well as on its theoretical significance. Indeed, it has been
suggested that both GI disturbances and altered gut
microflora could make a child with a genetic predis-
position for ASD more prone to express the autistic
phenotype or increase the severity of the autistic
behavior [17, 34, 42]. If this hypothesis was true then
it would be plausible to expect that strategies aimed
at restoring normal gut microbiota, such as probiotics
supplementation in the diet, may represent a non-
pharmacological option not only for GI disturbances
[43], but also for behavioral and neurophysiological
abnormalities associated with ASD.
Probiotics are live microorganisms thought able to
stabilize the mucosal barrier by increasing mucin expres-
sion, reducing bacterial over growth, stimulating mucosal
immunity (secretory Immunoglobulin A), and synthesiz-
ing antioxidant substances [32, 44]. Accordingly to their
balancing role on the intestinal microbiota, and to their
anti-proliferative activity on Clostridium species [45–49],
probiotics may represent a treatment in disorders in
which dysbiosis and increased intestinal permeability have
been reported, including ASD [32, 50].
Moreover, a further possible effect of probiotic supple-
mentation could be related to a reduction of metabolites
of exogenous toxic substances, through an indirect effect
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on their absorption by the “leaky gut”. After all, research
studies strongly support a significant contribution of
environmental factors in addition to genetic factors in
ASD etiology [51]. A class of chemical pollutants which
has been recently investigated in ASD is represented by
phthalates, chemicals widely used as plasticizers, sol-
vents and additives in many consumer products [52, 53].
To our knowledge, four different studies explored the
effects of probiotics in ASD [34, 54–56], but none of
them was designed or powered to assess significant
differences in clinical outcomes or identify adverse
effects [57]. Although all aforementioned studies showed
changes in gut flora after the implementation diet with
probiotics, only some of them analyzed the correlations
with GI symptoms [34, 56].
Among these four studies [34, 54–56], only Parracho
et al. [54] detected significant behavioral changes in
ASD patients treated with probiotics compared to ASD
individuals treated with placebo. Kaluzna-Czaplinska
and colleagues [55] found significant metabolic modifi-
cations in ASD after probiotic administration. Two in-
vestigations limited their findings to a strong positive
correlation between autism severity and the severity of
GI dysfunction [34, 56] without analyzing the effects of
probiotics on ASD clinical features. Although encour-
aging and supported by more robust preclinical evidence
[50], data on beneficial GI and behavioral effects in ASD
populations after probiotic treatment needs yet to be
established in well-controlled clinical trials [57, 58].
Objectives (Research aims and hypothesis)
Children with ASD and GI symptoms could represent a
distinct ASD endophenotype with specific clinical and
neurophysiological features. The exploitation of strat-
egies which can restore normal gut microbiota, and
reduce the gut production and absorption of toxins,
such as probiotics, may represent a non-pharmacological
option in the treatment of GI disturbances in ASD.
Moreover, a treatment with probiotics in this subgroup
of children with ASD, acting on the gut microflora and
on the systemic inflammatory status, could modify their
brain activity and function, possibly leading to significant
improvement of their behavioral and developmental
profiles.
The main aim of this study is to determine the effects
of supplementation with a probiotic mixture (Vivomixx®)
in ASD children with or without GI symptom. In par-
ticular, modifications on ASD core deficits, on cognitive
and language development, and on specific GI symp-
toms will be assessed. The concomitant changes that are
associated with administered treatment will be evaluated
on a cluster of plasmatic, urinary and fecal biomarkers
related to abnormal intestinal function as well as on
neurophysiological patterns.
An ancillary aim of the study will be to determine the
environmental exposure to phthalates (chemical pollu-
tant) in ASD children, and to evaluate the possible
effects of probiotics on their urinary concentrations.
As for the trial design, the study will be a double-blind
randomized controlled trial with a nutritional supple-
ment, with four parallel arms, an allocation ratio of 1:1,
and a superiority framework.
Methods/Design
Participants
We aim to enroll 100 preschoolers with ASD who will
be recruited from the Child and Adolescence Mental
Health Services of Tuscany Region, and from the Unit of
Child Psychiatry and the Unit of Child Rehabilitation of
IRCCS Stella Maris Foundation (Pisa, Italy). This is a
tertiary care University Hospital with a unit, exclusively
dedicated to ASD, who receives approximately 250
patients per year (mostly preschool children) for diagnosis
and treatment from all over Italy. All children recruited
will be assessed at IRCCS Stella Maris Foundation.
The following inclusion and exclusion criteria will be
adopted:
Inclusion criteria
a. age-range: 18–72 months. The interest in assessing the
effects of probiotic supplementation in preschoolers
with ASD relies on the strong recommendation to lead
early treatments in ASD, given the demonstrated
positive impact of early interventions on the core
symptoms of the disorder [59].
b. ASD diagnosis according to DSM-5 (Diagnostic and
Statistical Manual of Mental Disorders-5th Edition)
criteria [1]: Participants must have a diagnosis of
an ASD as assessed by a senior child psychiatrist
with a specific expertise in clinical evaluation of
ASD according to DSM-5 criteria before their
recruitment in the study.
Exclusion criteria
a. brain anomalies detected by Magnetic Resonance
Imaging; b. neurological syndromes or focal neurological
signs; c. anamnesis of birth asphyxia, severe premature
birth (≤28 gestational weeks) or perinatal injuries; d. epi-
lepsy; e. significant sensory impairment (e.g., blindness,
deafness); f. diagnosis of organic GI Disorder (i.e. gastro-
esophageal reflux, food allergies, IBD); g. diagnosis of
Coeliac Disease; h. special diet (i.e. gluten-free diet,
casein-free diet, high-protein diet, ketogenic diet).
The criteria from a. to e. are intended to exclude
children affected by not idiopathic forms of ASD or by
particular endophenotypes of the disorder as the “ASD
plus epilepsy” one. The criteria f. and g. are intended to
exclude children with not idiopathic or not functional
Santocchi et al. BMC Psychiatry  (2016) 16:183 Page 3 of 16
GI disorders. Children already enrolled in dietetic treat-
ment studies will not be included (criteria h.) given the
possible interferences of such diets on GI system during
the probiotic/placebo supplementation.
Baseline assessment
At the time of enrollment (Time 0 - T0), each research
participant will undergo a comprehensive clinical, bio-
chemical and electrophysiological evaluation in order to
establish the baseline of the primary and secondary out-
come measures (Table 1).
Clinical evaluation will include neurological and psychi-
atric examination along with standardized assessment of GI
symptoms, autism severity, sensory-behavioral features,
comorbid symptoms, parental stress, cognitive develop-
ment, adaptive functioning, and language abilities.
At T0 each subject will be classified as belonging to
the GI group or to the Non-Gastro Intestinal (NGI)
group on the basis of the presence of significant GI
symptoms measured through the Gastrointestinal Sever-
ity Index (GI Severity Index) [60]. A total score of 4 and
above at the GI Severity Index (with at least 3 score
Table 1 Scheme of the study
TIMEPOINT of visit/assessment Baseline 15 days (call interview) 3 months 6 months- end of the study
Enrollment
Information and informed consent ✓
Randomization-allocation ✓
Interventions
Probiotic Intervention
Placebo Intervention
Assessment
Physical examination including anthropometric measures and
abdominal tenderness
✓ ✓ ✓
Drug compliance and adverse event assessment ✓ ✓ ✓
Weekly food diaries ✓ ✓
ADI-R ✓
Outcome measures
ADOS 2 ✓ ✓
CARS ✓ ✓
RBS-R ✓ ✓ ✓
Sensory Profile ✓ ✓ ✓
SCQ ✓ ✓ ✓
GI Severity Index ✓ ✓ ✓
CBCL 1.5-5 ✓ ✓ ✓
PSI ✓ ✓ ✓
VABS-II ✓ ✓
Mc Arthur-CDI ✓ ✓ ✓
GMDS-ER ✓ ✓
Blood sample: LPS, Leptin, Resistin, TNF-α, IL-6, PAI-1 ✓ ✓
Urinary sample: Phtalates ✓ ✓ ✓
Fecal sample: Calprotectin ✓ ✓ ✓
High-density EEG registration: power, asymmetry index and
coherence in the different frequency bands
✓ ✓
Legend: ADI-R Autism Diagnostic Interview-Revised, ADOS-2 Autism Diagnostic Observation Schedule- Second Edition, CARS Childhood Autism Rating Scale, RBS-R
Repetitive Behavior Scale-Revised, SCQ Social Communication Questionnaire, GI Severity Index Gastro-Intestinal Severity Index, CBCL 1.5-5 Child Behavior Checklist
1.5-5, PSI Parenting Stress Index, VABS-II Vineland Adaptive Behavior Scale-Second Edition, Mc Arthur-CDI MacArthur-Bates Communicative Development Inventories,
GMDS-ER Griffiths Mental Development Scale-Extended Revised, LPS Lipopolysaccharide, TNF–α Tumor Necrosis Factor-α, IL-6 Interleukin-6, PAI–1 Plasminogen Activator
Inhibitor-1, EEG Electroencephalography
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points from the first six items of the scale) will be
considered clinically significant for the classification of a
subject within the GI group.
At T0 blood, urinary and fecal samples will be also
collected from each subject in order to perform bio-
chemical evaluation. Specifically, blood samples will be
collected to measure levels of leptin, resistin and inflam-
matory markers: TNF- α, IL-6, LPS and Plasminogen
Activator Inhibitor-1 (PAI-1); urinary samples will be
collected for the analysis of urinary concentrations of
primary and secondary metabolites of phthalates; fecal
samples will be collected for the analysis of fecal calpro-
tectin levels.
Neurophysiological patterns will be assessed through
QEEG measures. Neurophysiological characterization
will be performed by collecting EEG (Electroencephalog-
raphy) data during 6–8 min of rest with eyes open. The
128-channel HydroCel Geodesic Sensor Net (HCGSN
128; Electrical Geodesics Inc., USA) system will be used
for recording the EEGs. After pre-processing, QEEG
techniques will be applied in order to extract relevant
features characterizing brain activation and connectivity.
Interventions
ASD participants belonging to the two groups (GI and
NGI) will be blind randomized 1:1 to regular diet with
probiotics or with placebo for 6 months. Therefore, four
subgroups will be obtained:
Group 1) GI symptoms and probiotics
Group 2) GI Symptoms and placebo
Group 3) Non-GI symptoms and probiotics
Group 4) Non-GI symptoms and placebo
The probiotic preparation selected for this study is a
mixture (Vivomixx®), each packet of which contains 450
billions of lyophilized bacterial cells belonging to eight
probiotic strains: one strain of Streptococcus thermophi-
lus DSM 24731, three strains of Bifidobacterium (B.
breve DSM 24732, B. longum DSM 24736, B. infantis
DSM 24737), and four strains of Lactobacillus (L. acid-
ophilus DSM 24735, L. plantarum DSM 24730, L. para-
casei DSM 24733, L. delbrueckii subsp. bulgaricus DSM
24734). Vivomixx® is a patented and marketed product
and it has been approved for the use in children. This
study protocol will require the oral administration of
Vivomixx® which is available in a water-soluble formula-
tion that can be dissolved directly in the mouth or in a
cold, not carbonated liquid. According to the daily
weight-based dose of Vivomixx® and the age and weight
range of ASD children who will be recruited in the
study, the protocol posology will be two packets a day
(900 billions bacteria) in the first month of treatment
and one packet a day (450 billions bacteria) in the
following 5 months of treatment.
The treatment will be administered to children at home
by their parents/legal guardian during the 6 months of the
treatment protocol. A treatment duration of 6 months has
been chosen in order to warrant a good colonization of
the gut, that requires 2–3 weeks on average, and its main-
tenance for a period of time long enough to determine
possible significant clinical changes.
The placebo’s packaging and organoleptic characteris-
tics will be identical to the probiotic ones. Each packet
of placebo will contain 4.4 g of maltose and silicon
dioxide.
It will not be possible to modify allocated interven-
tions for a given trial participant. Participants will dis-
continue interventions as a consequence of intolerable
adverse events reported by parents/legal guardians or if
requested by their parents/legal guardians as a free
choice.
The suspension of any other treatment or intervention
effective and recommended by current guidelines in
ASD will not be required during the experimental proto-
col of treatment with probiotic/placebo.
In order to improve adherence to intervention proto-
cols, parents/legal guardians will have the possibility of
contact the research team by phone or e-mail every time
they will need for assistance and information. Periodical
call and direct interviews to parents/legal guardians at
several time-points (Table 1) will be useful for monitor-
ing adherence.
Mid-time assessment
After 3 months from the enrollment (Time 1 - T1), each
subject will undergo a second clinical and biochemical
evaluation in order to obtain a mid-time level of some of
the secondary clinical and biochemical outcome mea-
sures (Table 1). Only urinary and fecal samples will be
collected in order to determine mid-time levels of urin-
ary phthalates and fecal calprotectin.
Anamnestic information about the compliance to the
protocol and possible side effects of the treatment will
be specifically investigated. Clinical evaluation will in-
clude neurological and psychiatric examination along
with standardized assessment of GI symptoms, autism
severity, sensory-behavioral features, comorbid symp-
toms, parental stress, and language abilities. Detailed
treatment data will be also collected.
Final assessment
After 6 months (Time 2 - T2) from the enrollment i.e. at
the end of the intervention, each subject will undergo a
final assessment through the same clinical, biochemical
and neurophysiological evaluations performed at T0 in
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order to establish the after-treatment modifications of all
the primary and secondary outcome measures.
Study design and methodologies
The study will be a double-blind randomized controlled
trial with a nutritional supplement and with four parallel
arms (see Table 2 for Trial Registration Data). The writ-
ten informed consent from a parent or legal guardian of
children will be obtained by one of the investigators in-
volved in the recruitment, after the study procedures will
be explained.
The assessment will be conducted through the admin-
istration of the golden standard diagnostic tools for ASD
and through the use of psychological testing and scales
currently used by scientific community for the definition
of core features and comorbid symptoms of ASD. All
these evaluations will be performed by a multidisciplin-
ary research team (see Table 3) composed by a pharma-
ceutical chemical doctor and experienced clinically
trained research child psychiatrists and child psycholo-
gists, who met standard requirements for research reli-
ability for Autism Diagnostic Observation Schedule-2
(ADOS-2) [61] and Autism Diagnostic Interview-
Revised (ADI-R) [62] (which will be described in detail
in the Outcome Measures section).
Plasma and urinary levels of inflammatory markers
(TNF-α, IL-6, PAI-1), leptin and resistin will be mea-
sured by Elisa immunoassay Kits using luminex Tech-
nology (Merck Millipore). Concentrations of phthalates
and their metabolites will be measured in plasma and
urine using LC-MS (Liquid Chromatography–Mass
Spectrometry). These measurements will be performed
at the molecular laboratory of Institute of Clinical Physi-
ology of National Research Council (Pisa, Italy).
As for the analysis of brain activity and neurophysio-
logical patterns of the recruited subjects, we will use the
HCGSN 128 system. All data processing will be run off-
line on a computer running EEGLAB and a Lab tool for
QEEG analysis. The EEG system HCGSN 128 consists
of an integrated hardware/software system for recording
and analyzing EEG signals from 128 channels. The pres-
ence of 128 channels distributed on the surface of the
head allows obtaining in a high-density EEG recording
with an inter-electrode distance of 35 mm for adults and
10 mm for children. Since the sensor net contains a
bigger number of electrodes in comparison with the
traditional EEG system, the representation of the distri-
bution of electric potentials on the scalp is much more
accurate. The net for the signals recording is constituted
by sponges that are immersed in a saline solution to
obtain the contact with the skin without abrasion. This
characteristic makes the net application faster and less
invasive for the subjects and make the system particu-
larly suitable for young children.
Assignment of interventions
After inclusion in the study and baseline assessment,
participants will be assigned to the GI group or to the
NGI group depending on their baseline scores at the GI
Severity Index [60], as previously described. Then, par-
ticipants of these two groups will blind receive a treat-
ment with probiotics or with placebo according to a
computer generating randomization sequence previously
determined by the company supplying probiotic and
matched placebo. The allocation ratio of intended num-
bers of participants will be 1:1 both in the GI and in the
NGI comparison groups so that the number of children
receiving probiotics or placebo will be identical respect-
ively in the two GI and in the two NGI groups.
Randomization will be made in blocks with random
sequences of independent block both in the GI and in
the NGI groups; the order of interventions will be vary
randomly within each block, so that the assignment
blocking schedules will be unpredictable. The study will
be double blind till its conclusion, so that subjects, care-
givers, all research investigators and all the outcomes as-
sessors will be blinded to treatment group assignment of
all subjects till the end of data collection and analysis.
The packages containing probiotics will be indistin-
guishable from those containing placebo and will be
enumerated progressively in the two clinical subgroups
(GI: from 1 to 50; NGI from 1 to 50). The allocation se-
quence will be concealed and the matching between the
randomization number and the contents of each package
(probiotics or placebo) will be written in sealed enve-
lopes (one for each recruited subject/randomization
number) stored at the Institute of Clinical Physiology
National Research Council (Pisa, Italy).
The research investigators will assign a number of
treatment to each of the recruited children on the basis
of their respective progressive order of enrollment inside
each of the two subgroups. So, the first child enrolled in
the GI subgroup will receive the treatment packages
labelled “GI1”, the second child enrolled in the GI
subgroup will receive the treatment packages labelled
“GI2”, the first child enrolled in the NGI subgroup will
receive the treatment packages labelled “NGI1” and so on.
Emergency unblinding will be permissible only in
circumstances of harms or serious adverse events. The
allocated intervention will be revealed to the parents/
legal guardians of the subject by a research collaborator
not involved in recruitment, treatment assignment or
outcome assessment.
Outcomes
We aim to evaluate the effects of administration of
probiotics in preschooler with ASD with and without GI
symptoms through the comparison of several clinical,
behavioral and electrophysiological variables in the four
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Table 2 Trial registration data
Data category Information
Primary registry and trial identifying number ClinicalTrials.gov NCT02708901
Date of registration in primary registry March 4, 2016
Secondary identifying numbers GR-2011-02348280
Source(s) of monetary or material support Sponsor: IRCCS Fondazione Stella Maris Collaborators: Ministry of Health, Italy, Istituto
di Fisiologia Clinica CNR
Primary sponsor IRCCS Fondazione Stella Maris
Secondary sponsor(s) Collaborators: Ministry of Health, Italy; Istituto di Fisiologia Clinica CNR
Contact for public queries Central Contact: ES, MD, PhD; Email: e.santocchi@fsm.unipi.it
Contact for scientific queries Study Officials: ES, MD, PhD, Study Principal Investigator; IRCCS Stella Maris Foundation,
Calambrone, Pisa, Italy, 56128, e.santocchi@fsm.unipi.it
Oversight Oversight Authorities: Italy Ministry of Health
FDA Regulated? No
IND/IDE Protocol? No
Review Board Approval Status: Approved
Approval Number: 126/2014
Board Name: Comitato Etico Pediatrico Regione Toscana
Board Affiliation: Servizio Sanitario Regione Toscana
Email: comitato.etico@meyer.it
Data Monitoring?: Yes
Brief title Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and
Neurophysiological Parameters
Official title Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and
Neurophysiological Parameters
Countries of recruitment Locations: Italy, IRCCS Stella Maris Foundation
Health condition(s) or problem(s) studied Conditions: Autism Spectrum Disorder
Intervention(s) Active comparator: Vivomixx®, Two packets (900 billions bacteria) per os (P.O.) daily x 1
month and one packet (450 billions bacteria) P.O. daily x 5 months
Placebo comparator: Two packets (4.4 g of maltose and silicon dioxide x 2) P.O. daily x 1
month and one packet (4.4 g of maltose and silicon dioxide) P.O. daily x 5 months
Key inclusion and exclusion criteria Eligibility: Minimum Age: 18 Months; Maximum Age: 72 Months; Gender: Both; Accepts
Healthy Volunteers?: No
Inclusion Criteria: age-range: 18–72 months; ASD diagnosis according to Diagnostic and
Statistical Manual of Mental Disorders-5 (DSM-5) criteria
Exclusion Criteria: brain anomalies detected by Magnetic Resonance Imaging (MRI);
neurological syndromes or focal neurological signs; anamnesis of birth asphyxia, severe
premature birth (≤28 gestational weeks) or perinatal injuries; epilepsy; significant sensory
impairment; diagnosis of organic GI Disorder (i.e. gastroesophageal reflux, food allergies,
Inflammatory Bowel Disease); diagnosis of Coeliac Disease; special diet (i.e. gluten-free
diet, casein-free diet, high-protein diet, ketogenic diet)
Study type Interventional
Allocation: Randomized; Intervention Model: Parallel Assignment; Number of Arms: 4;
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Phase: Phase 4
Date of first enrolment November 2015
Target sample size 100
Recruitment status Recruiting
Primary outcome(s) Changes in severity level of ASD symptomatology (Time Frame: 6 months; not designated
as safety issue)
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subgroups identified. Only at the baseline, the ADI-R
[62], a highly-structured interview considered one of the
golden standard tool for diagnosis of ASD, will be ad-
ministered to parents to obtain a standardized symptom
profile of each child. Medical history and detailed treat-
ment data will be also collected. As previously described,
outcome variables will be assessed at three time points:
at the baseline assessment (T0), after an interval of
3 months (T1), and at the end of intervention, after an
interval of 6 months from the baseline assessment (T2).
All the outcome variables will be assessed in both
groups (GI and NGI) and in their respective subgroups
in order to determine the effects of probiotics compared
with placebo on gastrointestinal symptoms, autistic
symptomatology, behavioral, biochemical and neuro-
physiological patterns (see Table 1).
Moreover, at the baseline, at T1 and at T2, the changes
in nutritional status will be evaluated by weight, height
and Body Mass Index (BMI) calculation, while the com-
pliance and endurance at probiotic/placebo treatment,
the concomitant drug consumption (with particular at-
tention at antibiotic treatment) and the possible adverse
events will be monitored by caregivers interview. The
treatment compliance and the adverse events will be
evaluated also after 15 days from T0 through a call inter-
view. Possible changes in food habits and nutrition will
Table 3 Composition, roles, and responsibilities of the research team coordinating and conducting the trial (Steering Committee),
of the Auditing Committee and of the G-BIA (Gut-Brain Interaction in Autism) group
Research leading team/Steering Committee
(see title page and author section for
members)
Roles and Responsibilities
• Principal Investigator
(Trained research child psychiatrist)
Design and conduct of the trial, preparation of protocol and revisions preparation of investigators
brochure (IB) and CRFs [case report forms], organizing steering committee meetings, recruitment
coordination, clinical assessment coordination, EEG recording coordination, intervention coordination,
adverse events monitoring, data collection and entry coordination, providing of annual and final
reports to the ethics committee and mid-time and final report to the Italian Ministry of Health,
publication of study reports.
• Sub-Investigator
(Trained research pharmaceutical chemical
doctor)
Design and conduct of the trial, preparation of protocol and revisions, preparation of IB and CRFs,
biochemical samples collection and analysis, biochemical measurement coordination, data collection
and entry coordination, contacts with the company supplying probiotic and matched placebo and
performing randomization and intervention assignment, coordination of statistical analysis, providing
of annual and final reports to the ethics committee and mid-time and final report to the Italian
Ministry of Health, publication of study reports.
• Trained research Biomedical Engineer EEG data processing, EEG statistical analysis
Contribution to the development of the study design
• Laboratory Technician Biochemical measurement
Contribution to the development of the study design
• Trained research child psychologist Clinical assessment and data collection and entry coordination
Contribution to the development of the study design
• Trained research child psychiatrist Clinical assessment and data collection and entry coordination
Contribution to the development of the study design
• Trained research child psychiatrist Managing of the unblinding of allocated concealed treatment to families by necessity (harms or
serious adverse events) - Contribution to the development of the study design
Auditing Committee
(see title page and author section for
members)
Roles and responsibilities
• Steering committee
• Senior trained research physicians
Reviewing progress of study trough periodic audits of all the relevant aspects of the clinical trial
management
G-BIA (Gut-Brain Interaction in Autism) group
(see Acknowledgment section for members)
Selection of children from involved Neuropsychiatric Centers; collection of data
Table 2 Trial registration data (Continued)
Key secondary outcomes Changes in GI symptomatology; changes in Electroencephalogram (EEG) power, coherence
and asymmetry; changes in levels of serum Lipopolysaccharide, Leptin, Resistin, Tumor
Necrosis Factor – α, Interleukin- 6, P Plasminogen Activator Inhibitor – 1; changes in levels
of fecal calprotectin; Changes in global ASD symptomatology assessed by Childhood
Autism Rating Scale, by Social Communication Questionnaire, changes in ASD
symptomatology: repetitive behaviors and sensory profiles, changes in Developmental
Quotient, in Adaptive Functioning, in Behavioral Profiles, and in parental stress (time
frame: 3 and 6 months; not designated as safety issue).
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be monitored through the collection and analysis of
weekly food diaries that parents/caregivers will fill in
during the 6 months of the treatment protocol.
In order to promote participant retention, given the
long follow-up of 6 months, appointments will be sched-
uled in accordance with families’ availability and there
will be periodical phone and e-mail contacts of parents/
caregivers of patients for monitoring retention. For par-
ticipants who will be “off-study” after the mid-time
assessment (T1), at least a partial mid-time follow-up
will be obtained from all the biochemical outcome mea-
sures and the clinical outcome measures collected at T1.
For participants who will drop out before T1, only the
data collected at T0 assessment will be analyzed in order
to permit a baseline comparison between the total popu-
lation of enrolled patients and the subset of patients
completing the treatment.
Primary outcome measure
The primary outcome is the improvement of severity
level of ASD symptomatology, measured with ADOS-2
[61] which is a semi-structured assessment of communi-
cation, social interactions, play, imagination, and stereo-
typed or repetitive behaviors for the diagnosis of ASD
with a demonstrated inter-rater reliability, test-retest
reliability, and internal validity [63]. In this study, the
primary outcome measures will be changes in the ADOS
Calibrated Severity Scores (ADOS-CSS). The ADOS raw
total scores have been already used as outcome mea-
sures in previous randomized clinical trials investigating
effects of interventions in ASD [64–67]. The ADOS-CSS
scores had more uniform distributions across develop-
mental groups, were less influenced by participant
demographics than raw totals; therefore, they are useful
in comparing assessments across time and identifying
trajectories of autism severity for clinical research [68].
Secondary outcome measures
a) Clinical outcome measures
The changes in the scores of the following scales and
questionnaires will be measured during the treatment in
order to evaluate the possible changes in the clinical
profiles in children treated with probiotics compared
with children treated with placebo (see Table 1).
The GI Severity Index [60] is a composite score
designed by Schneider and colleagues to capture signs
and symptoms of GI distress most commonly reported
by parents of children with ASD. The index was con-
structed by adapting a modified Truelove and Witts
Severity Index used for clinical trials in ulcerative colitis
[69] to incorporate a total of nine variables relating to
GI signs and symptoms: constipation, diarrhea, average
stool consistency, stool smell, flatulence, abdominal pain,
unexplained daytime irritability, nighttime awakening,
and abdominal tenderness. We will collect data about
the first eight variables adapting the original items in a
self-report questionnaire filled-in by parents of children
about the last 3 months. The variable “Abdominal ten-
derness” will be assessed during the physical exam per-
formed at T0, T1 and T2 by a research physician.
The Childhood Autism Rating Scale (CARS) [70] con-
sists of 15 items on socialization, communication, emo-
tional responses, and sensory sensitivities intended to
measure the presence and severity of ASD. The child is
rated on each item based on the clinician’s observation
of the child’s behavior throughout the evaluation as well
as on the parent’s report. CARS classifies a child as hav-
ing mild, moderate, or severe autism, or no autism.
The Social Communication Questionnaire (SCQ) [71]
is a self-report parent questionnaire with a Current
Form which explore ASD specific symptoms in the last
3 months through 40 yes-or-no items.
The Child Behavior Checklist 1.5-5 (CBCL 1.5-5) [72]
is a questionnaire completed by the parents intended to
gather information about the child's behavior and which
provides scores for seven syndrome scales (Emotionally
Reactive, Anxious/Depressed, Somatic Complaints, With-
drawn, Aggressive Behavior, Attention Problems and Sleep
Problems), three summary scales (i.e., Internalizing, Exter-
nalizing and Total Problems) and five DSM-Oriented scales
(Affective Problems, Anxiety Problems, Pervasive Develop-
mental Disorder Problems, Attention Deficit Hyperactivity
Disorder Problems, and Oppositional Defiant Problems).
The Sensory Profile [73] is a self-report questionnaire
which explore sensory processing in children through
several items grouped by sensory processing, modula-
tion, and behavioral and emotional responses. The nine
factor groupings characterize children by their respon-
siveness to sensory input including Sensory seeking,
Emotional reactive, Low endurance/tone, Oral sensory
sensitivity, Inattention/distractibility, Poor registration,
Sensory sensitivity, Sedentary, and Fine motor/perceptual.
The Repetitive Behavior Scale-Revised (RBS-R) [74] is
a questionnaire completed by the parents informing for
the presence of a broad spectrum of repetitive behaviors,
and recently applied in Italian preschoolers with ASD
[75]. It is composed of 43-item scale measuring the
breadth of repetitive behavior in children, adolescents,
and adults with ASD. It consists of six subscales that
have no overlap of item content: Stereotyped Behavior,
Self-injurious Behavior, Compulsive Behavior, Routine
Behavior, Sameness Behavior, and Restricted Behavior.
The Parenting Stress Index (PSI) [76] is a self-report
questionnaire designed to evaluate the degree of stress
in the parent–child relationship. It yields a Total Score
and three domain scores.
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The Vineland Adaptive Behavior Scale II (VABS-II)
[77] is a widely used parent interview scale that assesses
adaptive functioning in the areas of communication,
daily living, socialization, and motor skills, as well as
yielding an adaptive behavior composite score.
Developmental level will be assessed trough the
Griffiths Mental Development Scales-Extended Revised
(GMDS-ER) [78], from which a Developmental Quotient
will be obtained.
The MacArthur-Bates Communicative Development
Inventories (CDIs) [79] are parent report instruments
which capture important information about children's
developing abilities in several domains of early language,
including vocabulary comprehension, production, ges-
ture use, and early grammar.
b) Electrophysiological outcome measures
The modification of the electrophysiological pattern at
rest will be evaluated by the comparison of the QEEG
features measured at T0 and T2 i.e. power, asymmetry
and coherence (a measure of connectivity) computed
within each characteristic frequency band of the brain.
c) Biochemical outcome measures
In order to value the effects of probiotics compared
with placebo on the intestinal and systemic inflamma-
tion, LPS, leptin, resistin, TNF-α, IL- 6, PAI–1, phtalates
and calprotectin will be measured before and after the
treatment (see Table 1).
Data management and confidentiality
All data will be entered both in paper Case Report
Forms (CRF) and in an electronic database immediately
after their collection at T0, T1 and T2. In order to pro-
tect confidentiality, CRF will be stored inside a locked
archive at IRCCS Stella Maris Foundation, while elec-
tronic data will be stored in a secured file inside the ser-
ver of the same institution. Numeric codes from 001 to
100 will be assigned to the recruited subjects on the
basis of their respective order of recruitment in the
study, and these codes will be reported in the CRF, in
the electronic database, in the phials containing bio-
logical samples and in the files containing EEG record-
ings (“P001” for the first recruited child, “P002” for the
second recruited child etc.). The matching between the
personal data of the recruited subjects and their assigned
numeric code will be reported in a separate secured elec-
tronic archive, along with their respective randomization
code (“GI” from 1 to 50 and “NGI” from 1 to 50, as de-
scribed above). Research collaborators not involved in out-
come assessment will be allowed to access the locked
archive and the electronic secured database in order to
enter collected data, using unambiguous, standardized ter-
minology and abbreviations to avoid misinterpretation. In
order to improve the accuracy of data entry and coding,
data entered in the electronic and paper sources will be
periodically verified by independent researchers.
The Principal Investigator (ES) and the Sub-
Investigator (LG) and the primary sponsor (IRCCS Stella
Maris Foundation) will have access at the end of the
study to the full trial dataset, and to the unblinding of
treatment assignment. The Italian Ministry of Health
can have access to the trial data anytime during or after
the trial.
Statistical analysis, power calculation and sample size
Sample size/power
The sample size calculation is based on primary out-
come assumption in the intervention and control group.
The primary outcome is the improvement of severity
level of ASD symptomatology, measured with ADOS-2
which defines the existence of a responder. A recent
study carried out by our group gives as an expected rate
of responder equal to 62 % [80].
Sample size calculations were performed using the
nQuery advisor 6.2 software, based on the primary effi-
cacy variable. Assuming a response rate of 62 % in the
placebo group and 90 % in the probiotic group, it was
calculated that 38 patients per treatment arm would be
sufficient to achieve 90 % power in detecting a treatment
difference based on 1-tail w2 test at a significance level
of 0.05. Therefore a number of 50 subjects to be enrolled
per group was considered sufficient to reach the goal ac-
counting for a certain degree of drop-out rate reported in
previous studies on the effects of probiotics [34, 54–56].
In order to achieve adequate participant enrolment to
reach target sample size, subjects will be recruited from
several clinical settings: 1) Child and Adolescence Men-
tal Health Services of Tuscany Region (Italy), that are
first level services for diagnosis and treatment of ASD,
dislocated all over the region; 2) The ASD Unit of Child
Psychiatry at IRCCS Stella Maris Foundation (Pisa,
Italy), a third level institute who receives approximately
250 patients per year (mostly preschool children) for
diagnosis from all over Italy; 3) The Unit of Child
Rehabilitation at IRCCS Stella Maris Foundation (Pisa,
Italy), that is a third level service for treatment of ASD
and receives approximately 40 patients per year. At each
clinical center involved in the study a child psychiatrist
will identified potential subjects, screening them among
all their patients through a specific checklist for inclu-
sion and exclusion criteria (Fig. 1). Then the child psych-
iatrist will informed parents/legal guardians of selected
children about the study, giving to them an advertising
brochure about the research aims and design and invited
them to contact the research team through phone call or
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e-mail in order to receive further information and to
give their agreement to participate. A dedicated phone
line will be available at IRCCS Stella Maris Foundation,
a research assistant responds during business hours and
an answering machine at all other times. All the study
visits will be carefully planned and scheduled in accord-
ance with the availability of the families in order to avoid
an interference with parents’ work or with the child re-
habilitation sections.
Data and statistical analysis
All data were will be collected and analyzed inde-
pendently of the investigators, who will not have ac-
cess to the data or to its analysis until the latter had
been completed. Baseline and demographic data will
be tested for balance between treatments using a 1-
way analysis of variance (ANOVA), w2 test, or Fisher
exact test, as appropriate. As designed by the proto-
col, the primary comparison for efficacy will be the
responder rate according to ADOS 2 score; the ana-
lysis will be carried out on the intent-to-treat popula-
tion, defined as all randomized patients who received
at least one dose of study medication. Dropouts will
be considered as no responders. Comparison between
treatment groups will be carried out by Cochran/
Mantel/Haenszel test for responder counts, controlled
for basal value, on either the total population of
enrolled patients and on the subset of patients com-
pleting the treatment. Post hoc-trend analysis of re-
sponders within each group will be carried out by the
Cochran-Armitage trend test. All data will be ana-
lyzed by means of SAS 8.2 Stat Procedures.
Fig. 1 Flow-chart of the phases of the RCT. Legend: ASD: Autism Spectrum Disorders, DSM-5: Diagnostic and Statistical Manual of Mental
Disorders-5th Edition, T0: Time 0, T1: Time 1, T2: Time 2, GI: Gastro Intestinal, NGI: Non-Gastro Intestinal ADI-R: Autism Diagnostic Interview-
Revised, ADOS-2: Autism Diagnostic Observation Schedule- Second Edition, CARS: Childhood Autism Rating Scale, RBS-R: Repetitive Behavior
Scale-Revised, SCQ: Social Communication Questionnaire, GI Severity Index: Gastro Intestinal Severity Index, CBCL 1.5-5: Child Behavior Checklist
1.5-5, PSI: Parenting Stress Index, VABS-II: Vineland Adaptive Behavior Scale-Second Edition, CDIs: MacArthur-Bates Communicative Development
Inventories, GMDS-ER: Griffiths Mental Development Scale-Extended Revised, LPS: Lipopolysaccharide, TNF–α: Tumor Necrosis Factor-α, IL-6:
Interleukin-6, PAI–1: Plasminogen Activator Inhibitor-1, EEG: Electroencephalography.
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Data monitoring
The Italian Ministry of Health has the role of oversight
and ultimate authority over all the activities of the study
and requires the research team to write a mid-time re-
port about the progress of the work and a final report
about the conclusion of the research.
In the mid-time report, interim analyses will be per-
formed on the rate of recruitment from each of the clin-
ical settings involved, and on adherence of recruited
participants to the treatment protocol. Baseline and
demographic data will be tested for balance between
dropouts and participants who will have completed the
protocol, using a 1-way analysis of variance (ANOVA),
w2 test, or Fisher exact test, as appropriate. Comparison
between treatment groups will be carried out at the
completion of the recruitment.
Any relevant changes to the study protocol which may
impact on the conduct of the study, or significant adminis-
trative aspects need to be communicate to the Italian Min-
istry of Health in order to obtain a formal authorization.
The Pediatric Ethic Committee of Tuscany Region has as-
sumed a role comparable to a Data Monitoring Commit-
tee, requiring the research team to write yearly reports
about the progress of the work and reports about any ad-
verse events. Any important protocol modification during
the trial need to be communicate to the Ethic Committee
in order to obtain a written authorization to a protocol
amendment. The Pediatric Ethic Committee of Tuscany
Region is independent from the sponsor and from trial in-
vestigators. Further details about it and its charter can be
found at http://www.meyer.it/index.php/ricerca-e-innova
zione/comitato-etico.
Periodic audits of all the relevant aspects of the clinical
trial management will be conducted by a team of senior
researchers not directly involved in the trial (FM, MAM,
EG). Audits will be planned every 2 months as research
meetings with an order of business related to the aspects
of the trial that will need a critical review (see Table 3).
Ethical issues and consent to participate
The study protocol (version 1- 14/07/2014) has been
approved by the Pediatric Ethic Committee of Tuscany
Region in July 2014 (Approval Number: 126/2014). The
current version is a protocol amendment (version 2- 14/
11/2014) which has been approved in December 2014.
The study will be carried out in accordance with recog-
nized ethical principles and good clinical practice for
clinical trials with food supplements. It will ensure the
protection of individuals as recommended in the Oviedo
Convention and in the Declaration of Helsinki. The sus-
pension of any other treatment or intervention effective
and recommended by current guidelines in ASD will not
be required during the experimental protocol of treatment
with probiotic/placebo. All the necessary information
about the study protocol, including the aims, methods,
potential risks and benefits related to experimentation,
and their right to refuse participation or to withdraw con-
sent at any time will be given to parents/legal guardians of
children recruited for the study through an information
sheet. No evaluations or other procedures will be carried
out without the prior obtaining of acceptance of all the
procedures described in the information sheet and signa-
ture of consent to participate by both parents/legal guard-
ians of the subjects. Moreover, parents/legal guardians of
all the children who will be recruited in the study will be
asked to give a specific and separate consent to publica-
tion of data in an anonymous way.
Parents/legal guardians will be asked to signed an add-
itional/ancillary consent for collection of additional
blood, urinary and fecal samples and for their storage at
−80 °C for future studies on the gut-brain connection
(i.e. metabolomic analysis or bacterial culture tests).
Patients that will be enrolled into the study will be
covered for non-negligent harm associated with the
protocol by an appropriate insurance.
Discussion
This randomized controlled trial will provide new infor-
mation on the clinical and neurophysiological effects of
probiotic treatment in preschoolers with ASD. To our
knowledge, to date only four studies explored the effects
of probiotics in ASD patients [34, 54–56] and they all
showed several limitations related to sample size, lack of
information about the probiotic oral supplementation or
concurrent medications and diet [57]. Adams and col-
leagues [34] compared GI flora and GI status from stool
samples of 58 children with ASD and 39 healthy typical
children of similar ages, and found lower levels of total
SCFAs in ASD group with a greater difference in chil-
dren with autism taking probiotics. In that study, GI
symptoms [34] were strongly correlated with the severity
of autism. However, information about the type of pro-
biotic oral supplementation was only partially explained.
Kaluzna-Czaplinska [55] administered oral supplementa-
tion of Lactobacillus acidophilus twice a day for
2 months to a group of ASD children and found signifi-
cant metabolic modifications, and an improvement in
the ability to carry out orders and concentration, but no
other behavioral or emotional effects. Parracho et al.
[54] reported in a large sample of children with ASD a
significant behavioral improvement in ASD treated with
Lactobacillus plantarum WCSF1 compared to ASD treated
with placebo. Recently, Tomova and colleagues [56] re-
vealed a strong positive correlation of autism severity with
the severity of GI dysfunction. In that study, probiotic diet
supplementation (a combination of Lactobacillus, Bifido-
bacter, and Streptococci, three times a day for 4 months)
normalized the microflora of autistic children. However,
Santocchi et al. BMC Psychiatry  (2016) 16:183 Page 12 of 16
the effects of probiotic diet supplementation on behaviors
were not investigated.
One of the possible outcome of this study is the identi-
fication of a subgroup of children with ASD and GI
symptoms that could represent a particular endopheno-
type of ASD characterized by an abnormal gut micro-
flora. We expect that these children, after a probiotic
treatment, could show changes in GI symptomatology
and in related blood, urinary and fecal biomarkers
through their effects in restoring the balance of intes-
tinal microflora, and in attenuating immunological ab-
normalities [32, 44]. Moreover, we expect that the
treatment with probiotics in individuals with ASD and
GI symptoms may produce also more significant im-
provement in autistic symptoms, in behavioral profiles,
in adaptive functioning and in cognitive and linguistic
development in comparison with individuals with ASD
and GI symptoms treated with placebo. As far as we
know, this is the first project that aims to examine the
impact of this treatment not only on clinical but also on
neurophysiological patterns and so it could provide new
insights into the gut-brain connection in autism. Accord-
ing to our knowledge, only few studies on the presence of
phthalates in subjects with ASD [52, 53] has been con-
ducted. One study of 48 children with ASD and 45 control
children reported that urinary concentrations of two
phthalates (5-OH-MEHP [mono-(2-ethyl-5-hydroxyhexyl)
1,2-benzenedicarboxylate] and 5-oxo-MEHP [mono-(2-
ethyl-5-oxohexyl) 1,2-benzenedicarboxylate]) were signifi-
cantly increased in the ASD group compared with the
control group [52]. Another study reported that 50 chil-
dren with ASD had decreased glucuronidation of diethyl-
hexyl phthalate, as measured by urinary metabolites,
compared with 53 age-matched controls with typical de-
velopment, despite similar phthalate exposure levels [53].
Notably, glucuronidation is a significant pathway involved
in the metabolism of xenobiotics and lower glucuronida-
tion might lead to a decreased detoxification capacity for
phthalates. Therefore, the current project could add new
data on the relationship between the presence of phtha-
lates, clinical features and neurophysiological patterns in
ASD. The expected risks for involved subjects are minimal
and related to possible side effects of treatment with pro-
biotics, which, as a dietary supplement, provides mild,
transient and not hazardous side effect for the child’s
health and to possible side effects related to draw blood
that can be considered mild and transient, too. Neverthe-
less, one of the possible study limitations is the adherence
of the families to the whole protocol, since it requires two
blood collections, three urinary and fecal collections and
two EEG registration and, even if these procedures are not
very invasive. During previous analogue researches in our
Institute, several families did not accept such kind of pro-
cedures for research purposes only. Moreover, adherence
of the families could be limited by the blind and random-
ized study design, given the possibility of not obtaining
immediate positive effects for their children if assigned to
the placebo groups, mostly due to the relatively long dur-
ation of the treatment protocol. Another possible limita-
tion of this study is the lack of a control sample of
typically developing children with and without GI symp-
toms in order to obtain a comparison of the biomarkers
levels, the phthalate presence and the neurophysiological
findings of ASD subjects. On the basis of the protocol re-
sults, if the presence of the hypothesized endophenotype
should be confirmed, a subsequent enrollment of a con-
trol matched group of children with typical development
will be taken into consideration.
Conclusions
In conclusion, the results of this project could provide a
multifaceted and wide characterization of ASD, and
investigate the relationship between intestinal inflamma-
tion and environmental toxicity. In this way, more solid
evidence on the role of treatment with probiotics on GI
function, and on behavioral and neurophysiological pa-
rameters could be obtained. At the present time, the ap-
proved and recommended treatments for ASD are
mainly based on rehabilitation, educational interventions
and psycho-pharmacological treatments. In children
with ASD, the GI dysfunction may be associated with a
higher rate of irritability, anger, aggressive behaviors and
sleep disturbances [4, 7]. Therefore, the treatment of
these symptoms by probiotics administration (a non-
pharmacological and relatively risk-free option) could
not only reduce overall costs for this disorder but also
improve compliance and adherence of these individuals
and of their families to educational and rehabilitation
treatments.
Trial status
Participant recruitment started in November 2015 and it
is currently underway. All participants recruited up until
now have been randomized and completed assessments
at T0, while some of them have completed assessments
at T1. The Study Completion will be in November 2017.
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